Research programme: integrin receptor antagonists - Johnson & Johnson Pharmaceutical Research and Development, LLC
Alternative Names: 3DP-229300; 3DP-336036Latest Information Update: 06 Mar 2008
Price :
$50 *
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Developer Johnson & Johnson Pharmaceutical Research & Development LLC
- Class Hydroxyquinolines; Propionic acids; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 antagonists; Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders
Most Recent Events
- 10 Sep 2004 Data presented at the 228th American Chemical Society National Meeting (228th-ACS-2004) have been added to the pharmacokinetics and Cancer pharmacodynamics sections ,
- 02 Aug 2004 A preclinical study has been added to the Cancer pharmacodynamics section
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson